in Mailand (Italien)

Prof. Eduardo Nobile Orazio is the Neurology Unit Director in Humanitas Research Hospital. 

His main areas of interest and specialisation are: diagnosis and treatment of neuromuscular diseases, in particular polyneuropathies, also including those of immunological origin such as Guillain Barré Syndrome (GBS) and the different clinical variants, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and the polyneuropathies associated with monoclonal gammopathy, the neuropathies and paraneoplastic neuronopathies and neuropathies in the course of haematologic diseases and from chemotherapy. 

Immunological diagnosis of autoimmune diseases of the peripheral and central nervous system, diagnosis and treatment of motor neurone disease with suspected paraneoplastic or immune genesis, diagnosis and treatment of Multiple Sclerosis and other autoimmune and inflammatory diseases of the central nervous system such as autoimmune and paraneoplastic encephalitis, diagnosis and treatment of Parkinson’s Disease and extrapyramidal diseases.

His areas of research are clinical and immunological diagnosis and treatment of the immune mediated polyneuropathies and, in particular, GBS, CIDP, MMN and polyneuropathy associated with monoclonal gammopathy including POEMS.

Prof. Eduardo Nobile Orazio has written over 230 scientific publications, held more than 85 university seminars or conferences. He has been a member of the SIN since 1991, of the European Neurological Society since 1989 until 2014, when he joined the European Academy of Neurology. Prof. Eduardo Nobile Orazio has also been a member of the American Academy of Neurology since 1998 and of the American Neurological Association since 2012.

Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=Nobile-Or  

Professor Carlo Selmi is leading the Rheumatology and Clinical Immunology Unit at Humanitas Research Hospital. 

Since 2009, he is the responsible of the Autoimmunity and Metabolic Laboratory, dedicated to the study of the possible mechanism linked to the progression of autoimmune diseases. 

The research focuses on four main areas: 

• - The epigenetic mechanisms that regulate the environment-genomic interface by influencing the susceptibility and the phenotype of chronic autoimmune and inflammatory diseases in the model of discordant monozygotic twins for disease. To date, the laboratory has biological sample of discordant couples for numerous diseases.
• - The target antigens of autoimmunity modifications that affect the development of the course of autoimmune diseases. In particular, the laboratory studies the post-translational modifications of joint collagen in rheumatoid arthritis.
• - The prevalence of non-organ autoantibodies, such as anti-nucleus and anti-ENAs and disease specific autoantibodies, such as anti-citrulline and anti-endomysium in a non-specific population of health adults and the significance of the positive founds over time.
• - Gender medicine in real-life, through the analysis of administrative databases.

The team holds dedicated clinics also for, spondiloarthritis and connetcive tissue disease, and it is active in articular ultrasound, videocapillaroscopy, arthrocenthesis and joint injection of steroid or hyaluronic acid.  The Division includes an inpatient clinic for complex cases. All group members are fluent in spoken and written English

Current Teaching Activity: Professor Selmi works as Assistant Professor of Rheumatology at the University of Milan since 2006. Furthermore, he holds a joint appointment as Assistant Professor of Medicine at the Division of Rheumatology of the University of California at Davis since 2005.

He is member of the American College of Rheumatology, American Association of Allergists and Immunologists, and the Italian Society of Rheumatology. He serves on the International Group for Research on Psoriatic Disease (GRAPPA) and the working group for autoantibody standardization within the ACR (ASC).

Publications: Selmi C[Author] - Search Results - PubMed (nih.gov)

Professor Antonino Spinelli is the Director of the Division of Colon and Rectal Surgery at Humanitas Research Hospital.

The Division of Colon and Rectal Surgery is one of the most important centres for colorectal disease, especially for procedures of sphincter preservation for rectal tumours, but also for chronic inflammatory bowel disease (Crohn disease, ulcerative rectal colitis…) and the surgical treatment of diverticular pathologies. 

Professor Spinelli carries out a constant research on minimally invasive surgeries, including the single-port surgery, mini-laparoscopy, low-impact surgery and trans-anal techniques (TATME, TAMIS, TTSS). Furthermore, the advanced postoperative recovering is another area of his interest.

He graduated as MD in 2001 at University of Milano. During his education, he won several scholarships: he trained ad University of Berlin Charitè for two years at the Department of General, Visceral and Transplantation Surgery. Also, he obtained his PhD on Surgical Phsyiopathology with a dissertation on enhanced recovery for laparoscopic colorectal surgery in 2011. 

Current Teaching Activity: he is Full Professor of Surgery at Humanitas University. 

Also, Professor Spinelli is general Secretary of the European Society of Coloproctology (ESCP) and Board Member of the Guidelines Committee (GulCom) of the European Crohn Disease and Colitis Organization (ECCO). He is Fellow of the American Society of Colon and Rectal Surgery (FASCRS), Honorary Fellow of the Czech Society of Surgery (CSS) and Honorary Member of the Brazilian College of Digestive Surgery (CBCD). 

He is a member of the International Organization for the study of Inflammatory Bowel Disease (IOIBD) and several other national and international scientific societies. 

In addition, Professor Spinelli serves as Associate Editor for Colorectal Disease (Journal of the Association of Coloproctology of Great Britain & Ireland, Royal College of Surgeons of England, of the European Society of Coloproctology and of the Spanish Society of Coloproctology – Asociación Española de Coloproctología), Diseases of the Colon and Rectum (official journal of the American Society of Colon and Rectal Surgeons), Journal of the Anus, Rectum and Colon (official journal of the Japan Society of Coloproctology).

He is Editorial Board Member of the Journal of Crohn’s Colitis (official journal of the European Crohn’s Colitis Organization), Advisory Board of Coloproctology (official journal of the German Society for Coloproctology – Deutsche Gesellschaft für Koloproktologie) and Editorial Board Member of Updates in Surgery (official journal of the Italian Society of Surgery – Società Italiana di Chirurgia).

Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.

He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977. 

In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa. 

Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University. 

Current Positions: 

• .Since 1997, he is the Director of the Department of Medical Oncology and Haematology, at Istituto Clinico Humanitas, Milan. Also, he is Member of the Ethics Committee of Istituto Clinico Humanitas and Director of Clinical Research in the same Institute since 2007.
• - Since 2008, he is Member of the Planning Committee, Ministry of Work and of Health and Social Politics, Rome, Italy.
• - Since October 2008, Professor Santoro is Counsellor of the Board of Directors of the Fondazione Humanitas for Research of Rozzano, Italy.
• - Since November 2008, he is Expert Member of the National Centre for the Prevention and Control of Disease, Ministry of Work and of Health and Social Politics (Rome, Italy).
• - Since February 2009, he is National Representative preparatory actions for the "European Partnership for Action against Cancer" Ministry of Work and of Health and Social Politics (Rome, Italy).
• - Since February 2009, Professor Santoro is member of National Italian Committee on the Research Network in Oncology, Ministry of Work and of Health and Social Politics (Rome, Italy).
• - Since May 2009, he is Coordinator of the Oesophageal-Stomach Cancer Group Coordinator of the Liver and Biliary Tree Cancer Group, Regional Oncology Commission – Lombardy Oncology Network.

In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009). 

Publications: santoro%a - Search Results - PubMed (nih.gov) 

Der Direktor der Doctor's Equipe Clinic. Der Erfinder des Microfat-Systems. Spezialist für Kiefer- und Gesichtschirurgie und ästhetisch-kosmetische Korrekturen.

Filippo de Marinis ist Direktor der Thoracic Oncology Unit am European Cancer Center (Mailand, Italien). Der Arzt leitet klinische Studien zu neuen Methoden bei der Behandlung von bösartigen Tumoren des Brustkorbs.

Die Erfahrung des Arztes beträgt mehr als 30 Jahre.

1978 schloss de Marinis sein Studium der Pneumologie an der Universität Sapienza in Rom ab. Zwischen 1983 und 1986 spezialisierte er sich auf Onkologie an der Katholischen Universität des Heiligen Herzens in Rom. Danach arbeitete Filippo de Marinis als Arzt am Carlo-Forlanini-Krankenhaus und am Institut für klinische Studien und pneumophysiologische Forschung. Seit 2007 lehrt er Pneumologie an der Privatuniversität Rom „Campus Biomedico“ („Biomedico Campus“) und an der Universität Sapienza Rom. Seit 2013 leitet der Professor die Abteilung für Thoraxkrebs am Europäischen Krebszentrum.

Arzttermin

Ein Termin bei Filippo de Marinis dauert zwischen 40 und 60 Minuten. In dieser Zeit erhebt der Arzt die Krankengeschichte des Patienten und gleicht sie mit den Untersuchungsergebnissen ab. Um eine genaue Diagnose zu stellen oder eine Operation zu planen, wird der Arzt bei Bedarf zusätzliche Tests verschreiben.

Wissenschaftliche Tätigkeit

Professor de Marinis ist Autor von 250 wissenschaftlichen Publikationen in 130 medizinischen Publikationen. Als einer der besten Spezialisten für die Behandlung von Lungenkrebs war er in den letzten 5 Jahren Redner auf 300 wissenschaftlichen Kongressen.

Der Arzt nimmt an nationalen und internationalen klinischen Studien neuer Medikamente teil.

Mitgliedschaft in Organisationen

• AIOT – Italienischer Brustkrebsverband;
• ESMO – Europäische Gesellschaft für Medizinische Onkologie;
• ASCO – Amerikanische Gesellschaft für klinische Onkologie;
• IASLC – International Association for the Study of Lung Cancer;
• ETOP – Europäische Plattform für thorakale Onkologie.

Barbara Alicia Erechek ist Direktorin der Abteilung für Strahlentherapie am Europäischen Krebszentrum in Mailand und Professorin für Radioonkologie an der Universität Mailand. Der Arzt ist spezialisiert auf Strahlentherapie bei allen Arten von Krebs und metastasierenden Tumoren.

• 26 Jahre Erfahrung in Strahlentherapie;
• 140 wissenschaftliche Publikationen.

Professor Erechek erhielt 1992 ihren medizinischen Abschluss an der Universität Danzig (Polen). Ihre Qualifikationen auf dem Gebiet der Radioonkologie verbesserte sie am Onkologischen Institut Warschau, der Universität Mailand, dem Beatson Cancer Center der Universität Glasgow (UK). Seit 1997 arbeitet der Mediziner als Facharzt für Strahlentherapie am Europäischen Krebszentrum. Seit 2015 leitet sie die Abteilung Strahlentherapie der Klinik.

Arzttermin

Ein Termin bei Dr. Erechek zur Bestrahlungsplanung dauert 30-50 Minuten. Der Arzt untersucht die Krankenakten und Testergebnisse des Patienten. Sie erklärt die Diagnose, spricht über die weitere Behandlung. Der Arzt gibt Empfehlungen, wie man sich am besten auf den Ablauf der Eingriffe vorbereitet, damit sie am angenehmsten sind.

Um eine Beratung von Professor Erechek zu erhalten, hinterlassen Sie eine Anfrage auf der Bookimed-Website. Der medizinische Koordinator wird sich mit Ihnen in Verbindung setzen, um das Datum und die Uhrzeit der Konsultation zu vereinbaren.

Wissenschaftliche Tätigkeit

Professorin Barbara Alicia Erechek ist Autorin von 140 wissenschaftlichen Publikationen.

Berufliche Erfolge und Auszeichnungen

Zwischen 1999 und 2003 erhielt Prof. Jereczek 4 Auszeichnungen von der Medizinischen Universität Danzig für Forschung auf dem Gebiet der Onkologie und Strahlentherapie.

Mitgliedschaft in Organisationen

• ESTRO - Europäische Gesellschaft für Therapeutische Radiologie und Onkologie;
• AIRO – Italienische Gesellschaft für Radioonkologie;
• European Oncology Institute New Protocol Review Committee, Mailand, Italien;
• Qualitätsausschuss für klinische Studien des Europäischen Instituts für Onkologie, Mailand, Italien.

Chirurg, Senologe

Onkologe-Urologe

Dr. Giuseppe Curigliano ist Leiter der Abteilung für frühe Arzneimittelentwicklung am Europäischen Institut für Onkologie und außerordentlicher Professor für medizinische Onkologie an der Universität Mailand in Italien. Er ist Gründungsmitglied und wissenschaftlicher Vorsitzender der International Cardio-Oncology Society (ICOS) und hat 2017 den ersten ESO Umberto Veronesi Award in Wien und 2017 das Fellowship der European Academy of Cancer Sciences in Paris erhalten.

Nicoletta Colombo ist Direktorin am Ovarian Cancer Center am IEO, Autorin zahlreicher Publikationen auf dem Gebiet der gynäkologischen Onkologie und Mitglied von ASCO, SGO und IGCS.